1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,600 | 7,320 | 03.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SELVITA Aktie jetzt für 0€ handeln | |||||
| 21.05. | Selvita S.A.: Selvita reports Q1 2026 results and launches strategic options review | 169 | PR Newswire | KRAKÓW, Poland, May 21, 2026 /PRNewswire/ -- Selvita S.A. (WSE: SLV), one of the leading Drug Discovery and Development organizations in Europe, has published its... ► Artikel lesen |
1 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 254,50 | +0,91 % | Stryker launches new small bone power tool for orthopedic procedures | ||
| PALATIN TECHNOLOGIES | 13,500 | 0,00 % | PALATIN TECHNOLOGIES INC - 8-A12B, Registration of securities | ||
| VIKING THERAPEUTICS | 25,400 | +0,79 % | Bull vs. Bear: The Quick Take on Viking Therapeutics Stock | ||
| COSCIENS BIOPHARMA | 1,520 | -6,17 % | COSCIENS Biopharma Inc. Reports Q1 2026 Results | TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company") today reported its financial and operating results for the first... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 60,22 | +5,65 % | Benchmark reiterates Halozyme stock Buy rating on long-term potential | ||
| ABCELLERA BIOLOGICS | 4,945 | -6,17 % | After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright | ||
| GLOW LIFETECH | 0,025 | -5,77 % | Glow Lifetech Corp.: Glow Lifetech Achieves Warrant-Free Capital Structure Following Elimination of 70 Million Warrants and 20% Reduction in Fully Diluted Shares | Toronto, Ontario--(Newsfile Corp. - June 2, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that all of its outstanding 8,900,000... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 261,80 | -0,53 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 2,820 | +2,92 % | BioLineRx Ltd.: BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update | - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) -
- Announced new GLIX1 data demonstrating potent anti-tumor... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 3,440 | -6,52 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Presents Real-World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026 | SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC
SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas... ► Artikel lesen | |
| PARATEK PHARMACEUTICALS | - | - | Paratek Pharmaceuticals: $1.3 Billion Financing Supports Radius Health Combination To Build Specialty Pharma Platform | ||
| MINERVA NEUROSCIENCES | 3,996 | -2,58 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| OVID THERAPEUTICS | 2,100 | +0,96 % | Ovid Therapeutics Inc.: Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors | NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant... ► Artikel lesen | |
| COCRYSTAL | 0,875 | -4,89 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer | BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen |
SELVITA SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,30 % bei einem Aktienkurs von 6,860 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SELVITA SA finden Sie auf Wallstreet Online.